Efficacy and safety of minimal dose (
Publication
, Journal Article
Denardo, SJ; Davis, KE; Reid, PR; Tcheng, JE
Published in: The American journal of cardiology
January 2003
Abciximab decreases adverse cardiac ischemic events, and in some subgroups, decreases the need for revascularization after percutaneous coronary intervention (PCI). However, abciximab may cause bleeding complications and thrombocytopenia after PCI. We hypothesized that the efficacy and safety of PCI would be maintained, if not improved, when performed using abciximab accompanied by only minimal doses (
Duke Scholars
Published In
The American journal of cardiology
ISSN
0002-9149
Publication Date
January 2003
Volume
91
Issue
1
Start / End Page
1 / 5
Related Subject Headings
- Cardiovascular System & Hematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Denardo, S. J., Davis, K. E., Reid, P. R., & Tcheng, J. E. (2003). Efficacy and safety of minimal dose (. The American Journal of Cardiology, 91(1), 1–5.
Denardo, S. J., K. E. Davis, P. R. Reid, and J. E. Tcheng. “Efficacy and safety of minimal dose (.” The American Journal of Cardiology 91, no. 1 (January 2003): 1–5.
Denardo SJ, Davis KE, Reid PR, Tcheng JE. Efficacy and safety of minimal dose (. The American journal of cardiology. 2003 Jan;91(1):1–5.
Denardo, S. J., et al. “Efficacy and safety of minimal dose (.” The American Journal of Cardiology, vol. 91, no. 1, Jan. 2003, pp. 1–5.
Denardo SJ, Davis KE, Reid PR, Tcheng JE. Efficacy and safety of minimal dose (. The American journal of cardiology. 2003 Jan;91(1):1–5.
Published In
The American journal of cardiology
ISSN
0002-9149
Publication Date
January 2003
Volume
91
Issue
1
Start / End Page
1 / 5
Related Subject Headings
- Cardiovascular System & Hematology
- 1102 Cardiorespiratory Medicine and Haematology